Profile - To The Moon

sinnedmal

Posts · 20Posts · 20
Following · 0Following · 0
Followers · 0Followers · 0

- sinnedmalsinnedmal
  ·2023-04-18
  Share your opinion about this news…
  Sorry, this post has been deleted
  361 Comment
  Like
  Share
  Report
- sinnedmalsinnedmal
  ·2022-03-24
  $Tiger Brokers(TIGR)$Why is it going down is it becos of the delist news?
  1.49K Comment
  1
  Share
  Report
- sinnedmalsinnedmal
  ·2021-07-29
  Hope that is good news
  Sorry, this post has been deleted
  466 Comment
  5
  Share
  Report
- sinnedmalsinnedmal
  ·2021-07-29
  Well hope that is good news
  S&P 500 ends off day's lows; Powell says Fed still a ways away from rate hikes
  NEW YORK (Reuters) - The S&P 500 ended little changed on Wednesday but off its session lows after th
  S&P 500 ends off day's lows; Powell says Fed still a ways away from rate hikes
  272 Comment
  4
  Share
  Report
- sinnedmalsinnedmal
  ·2021-07-22
  Hope BNGO also go up
  4 Biotech Stocks That Could Be Bargains
  Biotech stocks have had an uneven 2021 so far. One major biotech fund, the iShares Nasdaq Biotechnol
  4 Biotech Stocks That Could Be Bargains
  340 Comment
  3
  Share
  Report
- sinnedmalsinnedmal
  ·2021-07-22
  Hope today shares perform
  Wall Street ends higher, powered by strong earnings, economic cheer
  NEW YORK, July 21 (Reuters) - Wall Street stocks posted their second straight daily gain on Wednesda
  Wall Street ends higher, powered by strong earnings, economic cheer
  326 2
  6
  Share
  Report
- sinnedmalsinnedmal
  ·2021-07-22
  $Bionano Genomics(BNGO)$Comeon Go up
  392 Comment
  Like
  Share
  Report
- sinnedmalsinnedmal
  ·2021-07-21
  $AMC Entertainment(AMC)$Hope tonight AMC goup further
  841 1
  4
  Share
  Report
- sinnedmalsinnedmal
  ·2021-07-16
  $Bionano Genomics(BNGO)$Wondering why isnt itgoing up with all the news
  434 Comment
  Like
  Share
  Report
- sinnedmalsinnedmal
  ·2021-07-02
  $Marin(MRIN)$18 is now near and if it is short squeeze cannot be just at 20 should be higherif it does happen
  385 Comment
  2
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3584144630683908","uuid":"3584144630683908","gmtCreate":1624541031667,"gmtModify":1624678817136,"name":"sinnedmal","pinyin":"sinnedmal","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/205c1921b582082aab6d0f69483e5f34","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":22,"tweetSize":20,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9944845591,"gmtCreate":1681803935913,"gmtModify":1681803939307,"author":{"id":"3584144630683908","authorId":"3584144630683908","name":"sinnedmal","avatar":"https://static.tigerbbs.com/205c1921b582082aab6d0f69483e5f34","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584144630683908","authorIdStr":"3584144630683908"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9944845591","repostId":"1177436345","repostType":2,"isVote":1,"tweetType":1,"viewCount":361,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9037513719,"gmtCreate":1648134880700,"gmtModify":1676534308355,"author":{"id":"3584144630683908","authorId":"3584144630683908","name":"sinnedmal","avatar":"https://static.tigerbbs.com/205c1921b582082aab6d0f69483e5f34","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584144630683908","authorIdStr":"3584144630683908"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>Why is it going down is it becos of the delist news?","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>Why is it going down is it becos of the delist news?","text":"$Tiger Brokers(TIGR)$Why is it going down is it becos of the delist news?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/9037513719","isVote":1,"tweetType":1,"viewCount":1488,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3585798914737532","authorId":"3585798914737532","name":"Virendra","avatar":"https://static.tigerbbs.com/018fc47f35970bfc7c8c3908ef1669ae","crmLevel":6,"crmLevelSwitch":0,"idStr":"3585798914737532","authorIdStr":"3585798914737532"},"content":"$Tiger Brokers(TIGR)$ shorties at play that's why mostly.","text":"$Tiger Brokers(TIGR)$ shorties at play that's why mostly.","html":"$Tiger Brokers(TIGR)$ shorties at play that's why mostly."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801562100,"gmtCreate":1627523549600,"gmtModify":1703491617751,"author":{"id":"3584144630683908","authorId":"3584144630683908","name":"sinnedmal","avatar":"https://static.tigerbbs.com/205c1921b582082aab6d0f69483e5f34","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584144630683908","authorIdStr":"3584144630683908"},"themes":[],"htmlText":"Hope that is good news","listText":"Hope that is good news","text":"Hope that is good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801562100","repostId":"1127264445","repostType":4,"isVote":1,"tweetType":1,"viewCount":466,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801561452,"gmtCreate":1627523407076,"gmtModify":1703491614352,"author":{"id":"3584144630683908","authorId":"3584144630683908","name":"sinnedmal","avatar":"https://static.tigerbbs.com/205c1921b582082aab6d0f69483e5f34","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584144630683908","authorIdStr":"3584144630683908"},"themes":[],"htmlText":"Well hope that is good news","listText":"Well hope that is good news","text":"Well hope that is good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801561452","repostId":"1127264445","repostType":4,"repost":{"id":"1127264445","kind":"news","pubTimestamp":1627514621,"share":"https://ttm.financial/m/news/1127264445?lang=&edition=fundamental","pubTime":"2021-07-29 07:23","market":"us","language":"en","title":"S&P 500 ends off day's lows; Powell says Fed still a ways away from rate hikes","url":"https://stock-news.laohu8.com/highlight/detail?id=1127264445","media":"Reuters","summary":"NEW YORK (Reuters) - The S&P 500 ended little changed on Wednesday but off its session lows after th","content":"<p>NEW YORK (Reuters) - The S&amp;P 500 ended little changed on Wednesday but off its session lows after the Federal Reserve said the U.S. economic recovery remains on track and Chair Jerome <a href=\"https://laohu8.com/S/POWL\">Powell</a> said the central bank was still a ways away from considering raising interest rates.</p>\n<p>Keeping the market in check, shares of tech giant <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc fell 1.2% after it forecast slowing revenue growth.</p>\n<p>In a news conference following the release of a new policy statement from the Fed, Powell also said the U.S. job market still had “some ground to cover” before it would be time to pull back from the economic support the U.S. central bank put in place in the spring of 2020 to battle the coronavirus pandemic’s economic shocks.</p>\n<p>“It looks like probably the most positive thing for the market was that they are nowhere near increasing interest rates,” said Alan Lancz, president, Alan B. Lancz &amp; Associates Inc, an investment advisory firm based in Toledo, Ohio.</p>\n<p>Right after the Fed statement, the S&amp;P 500 index reversed slight declines though it still ended a hair lower on the day.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> have been worried about how rising inflation and a spike in COVID-19 cases might impact the central bank’s plan to potentially start withdrawing its stimulus.</p>\n<p>The central bank also said that higher inflation remained the result of “transitory factors.” The Fed kept its overnight benchmark interest rate near zero and left unchanged its bond-buying program.</p>\n<p>The <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> ended higher and shares of Google parent <a href=\"https://laohu8.com/S/GOOG\">Alphabet</a> Inc hit an all-time high as a surge in advertising spending helped it post record quarterly results. The stock ended up 3.2%.</p>\n<p>The Dow Jones Industrial Average fell 127.59 points, or 0.36%, to 34,930.93, the S&amp;P 500 lost 0.82 point, or 0.02%, to 4,400.64 and the Nasdaq Composite added 102.01 points, or 0.7%, to 14,762.58.</p>\n<p>The Fed’s statement came at the conclusion of its latest two-day policy meeting.</p>\n<p>“They had a chance to signal they were going to become more hawkish and they chose not to take it. The most important thing is they are predictable and they are remaining predictable,” said Ellen Hazen, portfolio manager at F.L. Putnam Investment Management in <a href=\"https://laohu8.com/S/WEBK\">Wellesley</a>, Massachusetts.</p>\n<p>In other earnings news, <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a> Corp ended down 0.1% even as a boom in cloud services helped it beat Wall Street expectations for revenue and earnings.</p>\n<p>Volume on U.S. exchanges was 9.86 billion shares, compared with a similar average for the full session over the last 20 trading days.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.85-to-1 ratio; on Nasdaq, a 2.61-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 42 new 52-week highs and no new lows; the Nasdaq Composite recorded 44 new highs and 67 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 ends off day's lows; Powell says Fed still a ways away from rate hikes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 ends off day's lows; Powell says Fed still a ways away from rate hikes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-29 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-ends-off-days-lows-powell-says-fed-still-a-ways-away-from-rate-hikes-idUSL1N2P435H><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - The S&P 500 ended little changed on Wednesday but off its session lows after the Federal Reserve said the U.S. economic recovery remains on track and Chair Jerome Powell said the ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-ends-off-days-lows-powell-says-fed-still-a-ways-away-from-rate-hikes-idUSL1N2P435H\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500",".IXIC":"NASDAQ Composite","SPXU":"三倍做空标普500ETF","SSO":"两倍做多标普500ETF",".SPX":"S&P 500 Index","IVV":"标普500指数ETF","OEX":"标普100","SH":"标普500反向ETF","SPY":"标普500ETF","OEF":"标普100指数ETF-iShares","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF",".DJI":"道琼斯"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-sp-500-ends-off-days-lows-powell-says-fed-still-a-ways-away-from-rate-hikes-idUSL1N2P435H","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127264445","content_text":"NEW YORK (Reuters) - The S&P 500 ended little changed on Wednesday but off its session lows after the Federal Reserve said the U.S. economic recovery remains on track and Chair Jerome Powell said the central bank was still a ways away from considering raising interest rates.\nKeeping the market in check, shares of tech giant Apple Inc fell 1.2% after it forecast slowing revenue growth.\nIn a news conference following the release of a new policy statement from the Fed, Powell also said the U.S. job market still had “some ground to cover” before it would be time to pull back from the economic support the U.S. central bank put in place in the spring of 2020 to battle the coronavirus pandemic’s economic shocks.\n“It looks like probably the most positive thing for the market was that they are nowhere near increasing interest rates,” said Alan Lancz, president, Alan B. Lancz & Associates Inc, an investment advisory firm based in Toledo, Ohio.\nRight after the Fed statement, the S&P 500 index reversed slight declines though it still ended a hair lower on the day.\nInvestors have been worried about how rising inflation and a spike in COVID-19 cases might impact the central bank’s plan to potentially start withdrawing its stimulus.\nThe central bank also said that higher inflation remained the result of “transitory factors.” The Fed kept its overnight benchmark interest rate near zero and left unchanged its bond-buying program.\nThe Nasdaq ended higher and shares of Google parent Alphabet Inc hit an all-time high as a surge in advertising spending helped it post record quarterly results. The stock ended up 3.2%.\nThe Dow Jones Industrial Average fell 127.59 points, or 0.36%, to 34,930.93, the S&P 500 lost 0.82 point, or 0.02%, to 4,400.64 and the Nasdaq Composite added 102.01 points, or 0.7%, to 14,762.58.\nThe Fed’s statement came at the conclusion of its latest two-day policy meeting.\n“They had a chance to signal they were going to become more hawkish and they chose not to take it. The most important thing is they are predictable and they are remaining predictable,” said Ellen Hazen, portfolio manager at F.L. Putnam Investment Management in Wellesley, Massachusetts.\nIn other earnings news, Microsoft Corp ended down 0.1% even as a boom in cloud services helped it beat Wall Street expectations for revenue and earnings.\nVolume on U.S. exchanges was 9.86 billion shares, compared with a similar average for the full session over the last 20 trading days.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.85-to-1 ratio; on Nasdaq, a 2.61-to-1 ratio favored advancers.\nThe S&P 500 posted 42 new 52-week highs and no new lows; the Nasdaq Composite recorded 44 new highs and 67 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172194353,"gmtCreate":1626942633072,"gmtModify":1703481004719,"author":{"id":"3584144630683908","authorId":"3584144630683908","name":"sinnedmal","avatar":"https://static.tigerbbs.com/205c1921b582082aab6d0f69483e5f34","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584144630683908","authorIdStr":"3584144630683908"},"themes":[],"htmlText":"Hope BNGO also go up","listText":"Hope BNGO also go up","text":"Hope BNGO also go up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172194353","repostId":"1197792637","repostType":4,"repost":{"id":"1197792637","kind":"news","pubTimestamp":1626941717,"share":"https://ttm.financial/m/news/1197792637?lang=&edition=fundamental","pubTime":"2021-07-22 16:15","market":"us","language":"en","title":"4 Biotech Stocks That Could Be Bargains","url":"https://stock-news.laohu8.com/highlight/detail?id=1197792637","media":"Barron's","summary":"Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnol","content":"<p>Biotech stocks have had an uneven 2021 so far.</p>\n<p>One major biotech fund, the <b><a href=\"https://laohu8.com/S/IBB\">iShares Nasdaq Biotechnology ETF</a></b>, which focuses on the bigger biotech players, is up 9%, just behind the&nbsp;S&amp;P 500 index,which is up 14.3%. Another important fund, the<b>&nbsp;<a href=\"https://laohu8.com/S/XBI\">Spdr S&amp;P Biotech Etf</a></b>, which spreads its assets across large and small biotech firms, is down 8.9% over the same period.</p>\n<p>The success of biotech standouts at developing Covid-19 vaccines at a rapid pace has drawn new attention and investors to the sector, and a sample of health care/biotech-dedicated funds tracked by Piper Sandler analyst Christopher Raymond has seen $1.3 billion in inflows so far this year.</p>\n<p>Picking the next big biotech stock, however, is tricky, and requires a depth of specialized knowledge. The best advice is generally to let the specialists at biotech-and-health-care-focused ETFs and mutual funds do the work for you.</p>\n<p>For those who want to make a pick on their own, one strategy is to search for value by looking for biotech stocks that trade at the steepest discount to where Wall Street analysts expect them to trade in the near term.</p>\n<h3><b>4 Undervalued Biotech Stocks</b></h3>\n<p>These are the four biotech stocks in the <b><a href=\"https://laohu8.com/S/IBB\">iShares Nasdaq Biotechnology ETF</a></b> and the <b><a href=\"https://laohu8.com/S/XBI\">Spdr S&amp;P Biotech Etf</a></b> with market values over $5 billion that trade the farthest below their average analyst price targets.</p>\n<table>\n <thead>\n  <tr>\n   <th>Company / Ticker</th>\n   <th>Recent Price</th>\n   <th>Average Target Price</th>\n   <th>Implied Gain</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>TG Therapeutics / TGTX</td>\n   <td>$37.32</td>\n   <td>$75.88</td>\n   <td>103.3%</td>\n  </tr>\n  <tr>\n   <td>Vir Biotechnology / VIR</td>\n   <td>$37.91</td>\n   <td>$74.29</td>\n   <td>96.0%</td>\n  </tr>\n  <tr>\n   <td>Ultragenyx Pharmaceutical / RARE</td>\n   <td>$85.49</td>\n   <td>$153.12</td>\n   <td>79.1%</td>\n  </tr>\n  <tr>\n   <td>Exelixis / EXEL</td>\n   <td>$16.67</td>\n   <td>$29.54</td>\n   <td>77.2%</td>\n  </tr>\n </tbody>\n</table>\n<p><i>Source: FactSet</i></p>\n<p>Analysts publish target prices for the stocks they cover, a price they expect the stock to hit at some point in the future, usually around a year out. Last month, we&nbsp;looked at the five health-care stocks in the S&amp;P 500 that trade the farthest below their average analyst&nbsp;price&nbsp;targets.</p>\n<p>This time, we’ve looked at the stocks in the SPDR S&amp;P Biotech and the iShares Biotechnology ETFs with market values of over $5 billion, and we found the four that trade the farthest below their average target prices, according to FactSet.</p>\n<p>We set the $5 billion market value as a floor to exclude some smaller stocks with just a couple of analysts covering them, for which average analyst target prices don’t mean much.</p>\n<p>The stocks that passed the screen are&nbsp;<b><a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology, Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical</a></b>, and<b>&nbsp;<a href=\"https://laohu8.com/S/EXEL\">Exelixis</a></b>, a group of interesting biotech stocks backed by substantial Wall Street analyst enthusiasm.</p>\n<p>The stock in the group that trades the farthest below its average analyst target price is TG Therapeutics, a biotech that focuses on the biology of B-cells, a type of white blood cell involved in the adaptive immune system. In February, the U.S. Food and Drug Administration approved a TG Therapeutics drug called Ukoniq to treatcertain lymphoma patients.</p>\n<p><b><a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a></b> stock climbed sharply this past December, as the company released positive data on a number of trials, including a trial of its drugumbralisib in certain leukemia patients.The stock rose 77.3% in December of 2020, but is down 27.9% this year.</p>\n<p>Analysts remain bullish on the stock. “We continue to think that the breadth of TGTX’s pipeline remains underappreciated at the current valuation,” wrote Cantor Fitzgerald analyst Alethia Young in a June 4 note.</p>\n<p>The average target price on TG Therapeutics is $75.88, according to FactSet, which implies an 103.3% gain from the stock’s recent price of $37.32.</p>\n<p>Another stock that passed our screen was Vir Biotechnology, the biotech firm that shot to prominence during the Covid-19 pandemic as one of the few focused on infectious disease. In May, the FDAauthorized a monoclonal antibody therapy&nbsp;jointly developed by Vir and&nbsp;<b><a href=\"https://laohu8.com/S/GSK\">GlaxoSmithKline PLC</a></b> to treat Covid-19 patients. Unlike other antibody therapies, Vir’s has proven to be effective against variant strains of the virus that cause Covid-19.</p>\n<p>Vir shares are up 41.7% so far this year. The company is also developing other products, including hepatitis B therapies that are in Phase 2 trials, and a flu antibody that is in Phase 1 trials.</p>\n<p>Of the eight analysts tracked by FactSet who maintain ratings on Vir, seven rate it at Buy or Overweight, while one rates it at Hold. Their average target price is $74.29, according to FactSet, which implies a gain of 96% over the stock’s recent price of $37.91.</p>\n<p>Also on our list is Ultragenyx, which develops drugs for rare diseases. Its approved therapies include Crysvita, which treats a genetic disease called X-linked hypophosphatemia, and Mepsevii, which treats a disease called Mucopolysaccharidosis VII, another rare genetic condition.</p>\n<p>The company is also developing gene therapies for other rare diseases. Ultragenyx stock has fallen 37.5% so far this year after a delay in the restart of its trials of a gene therapy for Angelman Syndrome, which had been put on clinical hold in the fall. Analysts, however, see a buying opportunity.</p>\n<p>“We find shares of RARE compelling at the current valuation,” Evercore ISI analyst Liisa Bayko wrote in a note upgrading the stock to Outperform from In Line in early May.</p>\n<p>The average analyst target price on Ultragenyx stock is $153.12, according to FactSet, implying a gain of 79.1% over the recent share price of $85.49.</p>\n<p>The final stock to pass our screen was <b><a href=\"https://laohu8.com/S/EXEL\">Exelixis</a></b>, an oncology-focused biotech with a number of products on the market, and a pipeline of cancer drugs. The stock is down 15.9% so far this year, after dropping 23.1% on a single day in late June when a trial of its drug cabozantinib in combination with another drugreturned disappointing data.</p>\n<p>The average analyst target price on the stock is $29.54, according to FactSet, which is 77.2% above the stock’s recent price of $16.62. That average target price may not mean much, however, as many of the target prices set by analysts have not been updated since the late-June drop.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Biotech Stocks That Could Be Bargains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Biotech Stocks That Could Be Bargains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 16:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnology ETF, which focuses on the bigger biotech players, is up 9%, just behind the S&P 500 index,which ...</p>\n\n<a href=\"https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","XBI":"SPDR S&P Biotech ETF","RARE":"Ultragenyx Pharmaceutical Inc","EXEL":"伊克力西斯","GSK":"葛兰素史克","TGTX":"TG Therapeutics Inc.","IBB":"生物科技指数ETF-iShares Nasdaq"},"source_url":"https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197792637","content_text":"Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnology ETF, which focuses on the bigger biotech players, is up 9%, just behind the S&P 500 index,which is up 14.3%. Another important fund, the Spdr S&P Biotech Etf, which spreads its assets across large and small biotech firms, is down 8.9% over the same period.\nThe success of biotech standouts at developing Covid-19 vaccines at a rapid pace has drawn new attention and investors to the sector, and a sample of health care/biotech-dedicated funds tracked by Piper Sandler analyst Christopher Raymond has seen $1.3 billion in inflows so far this year.\nPicking the next big biotech stock, however, is tricky, and requires a depth of specialized knowledge. The best advice is generally to let the specialists at biotech-and-health-care-focused ETFs and mutual funds do the work for you.\nFor those who want to make a pick on their own, one strategy is to search for value by looking for biotech stocks that trade at the steepest discount to where Wall Street analysts expect them to trade in the near term.\n4 Undervalued Biotech Stocks\nThese are the four biotech stocks in the iShares Nasdaq Biotechnology ETF and the Spdr S&P Biotech Etf with market values over $5 billion that trade the farthest below their average analyst price targets.\n\n\n\nCompany / Ticker\nRecent Price\nAverage Target Price\nImplied Gain\n\n\n\n\nTG Therapeutics / TGTX\n$37.32\n$75.88\n103.3%\n\n\nVir Biotechnology / VIR\n$37.91\n$74.29\n96.0%\n\n\nUltragenyx Pharmaceutical / RARE\n$85.49\n$153.12\n79.1%\n\n\nExelixis / EXEL\n$16.67\n$29.54\n77.2%\n\n\n\nSource: FactSet\nAnalysts publish target prices for the stocks they cover, a price they expect the stock to hit at some point in the future, usually around a year out. Last month, we looked at the five health-care stocks in the S&P 500 that trade the farthest below their average analyst price targets.\nThis time, we’ve looked at the stocks in the SPDR S&P Biotech and the iShares Biotechnology ETFs with market values of over $5 billion, and we found the four that trade the farthest below their average target prices, according to FactSet.\nWe set the $5 billion market value as a floor to exclude some smaller stocks with just a couple of analysts covering them, for which average analyst target prices don’t mean much.\nThe stocks that passed the screen are TG Therapeutics, Vir Biotechnology, Inc., Ultragenyx Pharmaceutical, and Exelixis, a group of interesting biotech stocks backed by substantial Wall Street analyst enthusiasm.\nThe stock in the group that trades the farthest below its average analyst target price is TG Therapeutics, a biotech that focuses on the biology of B-cells, a type of white blood cell involved in the adaptive immune system. In February, the U.S. Food and Drug Administration approved a TG Therapeutics drug called Ukoniq to treatcertain lymphoma patients.\nTG Therapeutics stock climbed sharply this past December, as the company released positive data on a number of trials, including a trial of its drugumbralisib in certain leukemia patients.The stock rose 77.3% in December of 2020, but is down 27.9% this year.\nAnalysts remain bullish on the stock. “We continue to think that the breadth of TGTX’s pipeline remains underappreciated at the current valuation,” wrote Cantor Fitzgerald analyst Alethia Young in a June 4 note.\nThe average target price on TG Therapeutics is $75.88, according to FactSet, which implies an 103.3% gain from the stock’s recent price of $37.32.\nAnother stock that passed our screen was Vir Biotechnology, the biotech firm that shot to prominence during the Covid-19 pandemic as one of the few focused on infectious disease. In May, the FDAauthorized a monoclonal antibody therapy jointly developed by Vir and GlaxoSmithKline PLC to treat Covid-19 patients. Unlike other antibody therapies, Vir’s has proven to be effective against variant strains of the virus that cause Covid-19.\nVir shares are up 41.7% so far this year. The company is also developing other products, including hepatitis B therapies that are in Phase 2 trials, and a flu antibody that is in Phase 1 trials.\nOf the eight analysts tracked by FactSet who maintain ratings on Vir, seven rate it at Buy or Overweight, while one rates it at Hold. Their average target price is $74.29, according to FactSet, which implies a gain of 96% over the stock’s recent price of $37.91.\nAlso on our list is Ultragenyx, which develops drugs for rare diseases. Its approved therapies include Crysvita, which treats a genetic disease called X-linked hypophosphatemia, and Mepsevii, which treats a disease called Mucopolysaccharidosis VII, another rare genetic condition.\nThe company is also developing gene therapies for other rare diseases. Ultragenyx stock has fallen 37.5% so far this year after a delay in the restart of its trials of a gene therapy for Angelman Syndrome, which had been put on clinical hold in the fall. Analysts, however, see a buying opportunity.\n“We find shares of RARE compelling at the current valuation,” Evercore ISI analyst Liisa Bayko wrote in a note upgrading the stock to Outperform from In Line in early May.\nThe average analyst target price on Ultragenyx stock is $153.12, according to FactSet, implying a gain of 79.1% over the recent share price of $85.49.\nThe final stock to pass our screen was Exelixis, an oncology-focused biotech with a number of products on the market, and a pipeline of cancer drugs. The stock is down 15.9% so far this year, after dropping 23.1% on a single day in late June when a trial of its drug cabozantinib in combination with another drugreturned disappointing data.\nThe average analyst target price on the stock is $29.54, according to FactSet, which is 77.2% above the stock’s recent price of $16.62. That average target price may not mean much, however, as many of the target prices set by analysts have not been updated since the late-June drop.","news_type":1},"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172195933,"gmtCreate":1626942577122,"gmtModify":1703481002761,"author":{"id":"3584144630683908","authorId":"3584144630683908","name":"sinnedmal","avatar":"https://static.tigerbbs.com/205c1921b582082aab6d0f69483e5f34","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584144630683908","authorIdStr":"3584144630683908"},"themes":[],"htmlText":"Hope today shares perform","listText":"Hope today shares perform","text":"Hope today shares perform","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/172195933","repostId":"2153477496","repostType":4,"repost":{"id":"2153477496","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626899252,"share":"https://ttm.financial/m/news/2153477496?lang=&edition=fundamental","pubTime":"2021-07-22 04:27","market":"us","language":"en","title":"Wall Street ends higher, powered by strong earnings, economic cheer","url":"https://stock-news.laohu8.com/highlight/detail?id=2153477496","media":"Reuters","summary":"NEW YORK, July 21 (Reuters) - Wall Street stocks posted their second straight daily gain on Wednesda","content":"<p>NEW YORK, July 21 (Reuters) - Wall Street stocks posted their second straight daily gain on Wednesday, with robust corporate earnings and renewed optimism about the U.S. economic recovery fueling a risk-on rally.</p>\n<p>All three major U.S. stock indexes added to their previous session's advance, placing all three within 1% of their all-time closing highs.</p>\n<p>Economically sensitive smallcaps , semiconductors&nbsp;and financials&nbsp;outperformed the broader market.</p>\n<p>\"It’s a seesaw going on between great earnings and a recovering market and concerns over whether the economy is going to slow down because of the (COVID-19) Delta variant,\" said Peter Tuz, president of Chase Investment Counsel in Charlottesville, Virginia. \"But we’re seeing strong earnings with generally positive guidance, and the feeling that (the Delta variant) can be managed.\"</p>\n<p>A rebound in travel helped fuel United Airlines'&nbsp;revenue beat, boosting its stock by 3.8%.</p>\n<p>The S&amp;P 1500 Airlines index&nbsp;gained 3.3%, while the S&amp;P 1500 Hotels, Restaurant and Leisure index advanced 2.9%.</p>\n<p>\"Earlier in the week those stocks suffered because of renewed fears that travel will slow down and all related industries will suffer, but those fears have gone away,\" Tuz added. \"Demand is continuing as expected, I don’t think the Delta fear is causing people to change their plans.\"</p>\n<p>Benchmark U.S. Treasury yields continued their bounce from five-month lows following a weak 20-year bond auction, which benefited rate-sensitive banks.</p>\n<p>Wrangling in Washington over the passage of a bipartisan $1.2 trillion infrastructure package progressed as Senate Democrats moved toward a planned procedural vote despite Republican appeals for a delay.</p>\n<p>The Dow Jones Industrial Average rose 286.01 points, or 0.83%, to 34,798, the S&amp;P 500 gained 35.63 points, or 0.82%, to 4,358.69 and the Nasdaq Composite added 133.08 points, or 0.92%, to 14,631.95.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, energy stocks</p>\n<p>were the big winners, jumping 3.5% with the help of surging crude prices .</p>\n<p>Second-quarter reporting season has shifted into overdrive, with 73 of the companies in the S&amp;P 500 having posted results. Of those, 88% have beaten consensus expectations.</p>\n<p>Among the winners, Chipotle Mexican Grill jumped 11.5% after the burrito chain beat earnings estimates and forecast strong current-quarter sales growth. The stock boasted the S&amp;P 500's largest percentage gain.</p>\n<p>Coca-Cola rose 1.3% after raising its full-year forecast.</p>\n<p>Interpuplic Group of Companies&nbsp;jumped 11.3% in the wake of its upbeat earnings release.</p>\n<p>Drugmaker Johnson &amp; Johnson&nbsp;forecast $2.5 billion in sales from its <a href=\"https://laohu8.com/S/AONE.U\">one</a>-shot COVID vaccine this year and hiked its sales estimates. It closed up a modest 0.6%.</p>\n<p>On the losing side, Netflix Inc late Tuesday reported slowing subscriber growth, sending its shares down 3.3%, the second-largest percentage loser in the S&amp;P 500.</p>\n<p>Harley-Davidson's&nbsp; second-quarter earnings release showed its turnaround plan appeared to be making progress, but the company lowered its operating income guidance due to tariffs from Europe, its second-biggest market. Its stock dropped 7.2%.</p>\n<p>Texas Instruments&nbsp;dipped more than 3% in extended trading following results posted after the bell.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.92-to-1 ratio; on Nasdaq, a 3.21-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 38 new 52-week highs and no new lows; the Nasdaq Composite recorded 66 new highs and 34 new lows.</p>\n<p>Volume on U.S. exchanges was 9.13 billion shares, compared with the 10.17 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends higher, powered by strong earnings, economic cheer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends higher, powered by strong earnings, economic cheer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-22 04:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, July 21 (Reuters) - Wall Street stocks posted their second straight daily gain on Wednesday, with robust corporate earnings and renewed optimism about the U.S. economic recovery fueling a risk-on rally.</p>\n<p>All three major U.S. stock indexes added to their previous session's advance, placing all three within 1% of their all-time closing highs.</p>\n<p>Economically sensitive smallcaps , semiconductors&nbsp;and financials&nbsp;outperformed the broader market.</p>\n<p>\"It’s a seesaw going on between great earnings and a recovering market and concerns over whether the economy is going to slow down because of the (COVID-19) Delta variant,\" said Peter Tuz, president of Chase Investment Counsel in Charlottesville, Virginia. \"But we’re seeing strong earnings with generally positive guidance, and the feeling that (the Delta variant) can be managed.\"</p>\n<p>A rebound in travel helped fuel United Airlines'&nbsp;revenue beat, boosting its stock by 3.8%.</p>\n<p>The S&amp;P 1500 Airlines index&nbsp;gained 3.3%, while the S&amp;P 1500 Hotels, Restaurant and Leisure index advanced 2.9%.</p>\n<p>\"Earlier in the week those stocks suffered because of renewed fears that travel will slow down and all related industries will suffer, but those fears have gone away,\" Tuz added. \"Demand is continuing as expected, I don’t think the Delta fear is causing people to change their plans.\"</p>\n<p>Benchmark U.S. Treasury yields continued their bounce from five-month lows following a weak 20-year bond auction, which benefited rate-sensitive banks.</p>\n<p>Wrangling in Washington over the passage of a bipartisan $1.2 trillion infrastructure package progressed as Senate Democrats moved toward a planned procedural vote despite Republican appeals for a delay.</p>\n<p>The Dow Jones Industrial Average rose 286.01 points, or 0.83%, to 34,798, the S&amp;P 500 gained 35.63 points, or 0.82%, to 4,358.69 and the Nasdaq Composite added 133.08 points, or 0.92%, to 14,631.95.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, energy stocks</p>\n<p>were the big winners, jumping 3.5% with the help of surging crude prices .</p>\n<p>Second-quarter reporting season has shifted into overdrive, with 73 of the companies in the S&amp;P 500 having posted results. Of those, 88% have beaten consensus expectations.</p>\n<p>Among the winners, Chipotle Mexican Grill jumped 11.5% after the burrito chain beat earnings estimates and forecast strong current-quarter sales growth. The stock boasted the S&amp;P 500's largest percentage gain.</p>\n<p>Coca-Cola rose 1.3% after raising its full-year forecast.</p>\n<p>Interpuplic Group of Companies&nbsp;jumped 11.3% in the wake of its upbeat earnings release.</p>\n<p>Drugmaker Johnson &amp; Johnson&nbsp;forecast $2.5 billion in sales from its <a href=\"https://laohu8.com/S/AONE.U\">one</a>-shot COVID vaccine this year and hiked its sales estimates. It closed up a modest 0.6%.</p>\n<p>On the losing side, Netflix Inc late Tuesday reported slowing subscriber growth, sending its shares down 3.3%, the second-largest percentage loser in the S&amp;P 500.</p>\n<p>Harley-Davidson's&nbsp; second-quarter earnings release showed its turnaround plan appeared to be making progress, but the company lowered its operating income guidance due to tariffs from Europe, its second-biggest market. Its stock dropped 7.2%.</p>\n<p>Texas Instruments&nbsp;dipped more than 3% in extended trading following results posted after the bell.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.92-to-1 ratio; on Nasdaq, a 3.21-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 38 new 52-week highs and no new lows; the Nasdaq Composite recorded 66 new highs and 34 new lows.</p>\n<p>Volume on U.S. exchanges was 9.13 billion shares, compared with the 10.17 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153477496","content_text":"NEW YORK, July 21 (Reuters) - Wall Street stocks posted their second straight daily gain on Wednesday, with robust corporate earnings and renewed optimism about the U.S. economic recovery fueling a risk-on rally.\nAll three major U.S. stock indexes added to their previous session's advance, placing all three within 1% of their all-time closing highs.\nEconomically sensitive smallcaps , semiconductors and financials outperformed the broader market.\n\"It’s a seesaw going on between great earnings and a recovering market and concerns over whether the economy is going to slow down because of the (COVID-19) Delta variant,\" said Peter Tuz, president of Chase Investment Counsel in Charlottesville, Virginia. \"But we’re seeing strong earnings with generally positive guidance, and the feeling that (the Delta variant) can be managed.\"\nA rebound in travel helped fuel United Airlines' revenue beat, boosting its stock by 3.8%.\nThe S&P 1500 Airlines index gained 3.3%, while the S&P 1500 Hotels, Restaurant and Leisure index advanced 2.9%.\n\"Earlier in the week those stocks suffered because of renewed fears that travel will slow down and all related industries will suffer, but those fears have gone away,\" Tuz added. \"Demand is continuing as expected, I don’t think the Delta fear is causing people to change their plans.\"\nBenchmark U.S. Treasury yields continued their bounce from five-month lows following a weak 20-year bond auction, which benefited rate-sensitive banks.\nWrangling in Washington over the passage of a bipartisan $1.2 trillion infrastructure package progressed as Senate Democrats moved toward a planned procedural vote despite Republican appeals for a delay.\nThe Dow Jones Industrial Average rose 286.01 points, or 0.83%, to 34,798, the S&P 500 gained 35.63 points, or 0.82%, to 4,358.69 and the Nasdaq Composite added 133.08 points, or 0.92%, to 14,631.95.\nOf the 11 major sectors in the S&P 500, energy stocks\nwere the big winners, jumping 3.5% with the help of surging crude prices .\nSecond-quarter reporting season has shifted into overdrive, with 73 of the companies in the S&P 500 having posted results. Of those, 88% have beaten consensus expectations.\nAmong the winners, Chipotle Mexican Grill jumped 11.5% after the burrito chain beat earnings estimates and forecast strong current-quarter sales growth. The stock boasted the S&P 500's largest percentage gain.\nCoca-Cola rose 1.3% after raising its full-year forecast.\nInterpuplic Group of Companies jumped 11.3% in the wake of its upbeat earnings release.\nDrugmaker Johnson & Johnson forecast $2.5 billion in sales from its one-shot COVID vaccine this year and hiked its sales estimates. It closed up a modest 0.6%.\nOn the losing side, Netflix Inc late Tuesday reported slowing subscriber growth, sending its shares down 3.3%, the second-largest percentage loser in the S&P 500.\nHarley-Davidson's  second-quarter earnings release showed its turnaround plan appeared to be making progress, but the company lowered its operating income guidance due to tariffs from Europe, its second-biggest market. Its stock dropped 7.2%.\nTexas Instruments dipped more than 3% in extended trading following results posted after the bell.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.92-to-1 ratio; on Nasdaq, a 3.21-to-1 ratio favored advancers.\nThe S&P 500 posted 38 new 52-week highs and no new lows; the Nasdaq Composite recorded 66 new highs and 34 new lows.\nVolume on U.S. exchanges was 9.13 billion shares, compared with the 10.17 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":326,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172192694,"gmtCreate":1626942538018,"gmtModify":1703481002272,"author":{"id":"3584144630683908","authorId":"3584144630683908","name":"sinnedmal","avatar":"https://static.tigerbbs.com/205c1921b582082aab6d0f69483e5f34","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584144630683908","authorIdStr":"3584144630683908"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>Comeon Go up","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>Comeon Go up","text":"$Bionano Genomics(BNGO)$Comeon Go up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172192694","isVote":1,"tweetType":1,"viewCount":392,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178401520,"gmtCreate":1626830094460,"gmtModify":1703765965600,"author":{"id":"3584144630683908","authorId":"3584144630683908","name":"sinnedmal","avatar":"https://static.tigerbbs.com/205c1921b582082aab6d0f69483e5f34","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584144630683908","authorIdStr":"3584144630683908"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Hope tonight AMC goup further&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Hope tonight AMC goup further&nbsp;","text":"$AMC Entertainment(AMC)$Hope tonight AMC goup further","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/178401520","isVote":1,"tweetType":1,"viewCount":841,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170117069,"gmtCreate":1626411913351,"gmtModify":1703759664617,"author":{"id":"3584144630683908","authorId":"3584144630683908","name":"sinnedmal","avatar":"https://static.tigerbbs.com/205c1921b582082aab6d0f69483e5f34","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584144630683908","authorIdStr":"3584144630683908"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>Wondering why isnt itgoing up with all the news&nbsp;","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>Wondering why isnt itgoing up with all the news&nbsp;","text":"$Bionano Genomics(BNGO)$Wondering why isnt itgoing up with all the news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170117069","isVote":1,"tweetType":1,"viewCount":434,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156245714,"gmtCreate":1625227625838,"gmtModify":1703738810300,"author":{"id":"3584144630683908","authorId":"3584144630683908","name":"sinnedmal","avatar":"https://static.tigerbbs.com/205c1921b582082aab6d0f69483e5f34","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3584144630683908","authorIdStr":"3584144630683908"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>18 is now near and if it is short squeeze cannot be just at 20 should be higherif it does happen","listText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>18 is now near and if it is short squeeze cannot be just at 20 should be higherif it does happen","text":"$Marin(MRIN)$18 is now near and if it is short squeeze cannot be just at 20 should be higherif it does happen","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/156245714","isVote":1,"tweetType":1,"viewCount":385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}